Intrinsiqq
Outlook Therapeutics Inc. logo

Outlook Therapeutics Inc. Insider Trading

OTLK

⊜ Compare
Cluster buy

4 insiders bought $2.6M of their own stock in 17 days.

Open-market purchases by executives and directors between Jul 29 and Aug 14. Buying is rarer than selling and says more, but it is one input, not a verdict.

Net open-market
+$2.87M
9 buys · 0 sales
Under a 10b5-1 plan
—
no sales
Insiders who bought / sold
7 / 0
executives and directors
Last open-market buy
Aug 2026
Aug 14, 2026

Get an email when OTLK's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Aug 14
    Lawrence A Kenyon
    Chief Financial Officer · bought 101,010
    —
    1699% of stake
  • Aug 14
    Robert Charles Jahr
    Chief Executive Officer · bought 151,515
    —
    New position
  • Aug 12
    Ghiath M. Sukhtian
    Director · bought 2,525,252 at $0.99
    $2.5M
    11% of stake
  • Jul 29
    Faisal Ghiath Sukhtian
    Director · bought 95,398 at $1.05
    100K
    76% of stake
  • Jun 2
    Yezan Munther Haddadin
    Director · bought 29,000 at $0.83
    24K
    78% of stake
  • May 28
    GMS Ventures & Investments
    Large holder · bought 8,539,709 at $0.59
    $5.04M
    63% of stake
  • May 27
    Faisal Ghiath Sukhtian
    Director · bought 122,174 at $0.41
    50K
    3593% of stake
  • May 26
    Yezan Munther Haddadin
    Director · bought 34,000 at $0.44
    15K
    1074% of stake
  • May 26
    Randy H Thurman
    Director · bought 5,000 at $0.43
    2K
    843% of stake
  • May 26
    Kurt J Hilzinger
    Director · bought 400,000 at $0.44
    176K
    1691% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch OTLK, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with OTLK

CompareIntrinsic value
SCNIScinai Immunotherapeutics Ltd.
$0.45-4.92%30
INBXInhibrx Biosciences, Inc.
$86.76+7.01%15
PLURPluri Inc.
$1.23-3.15%30
PROKProKidney Corp
$1.12+4.67%10
IMAImageneBio, Inc.
$4.10+1.99%10
HUMAHumacyte, Inc.
$0.45+2.04%10
CRDFCardiff Oncology Inc.
$0.87+1.03%36
PALIPalisade Bio Inc.
$1.25+1.63%20

Spot a number that looks wrong? Check it in OTLK's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing OTLK

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.